Severe Eosinophilic asthma research hub
3 indexed studies · 2 currently recruiting
- recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)
This study is testing a new medicine, dexpramipexole, for adults with severe asthma that affects their eosinophils (a type of white blood cell). We want to see if it reduces severe asthma attacks and improves breathing and quality of life over 52 weeks.
Romania · Bulgaria · Poland - completedNot Applicable
Study of the effect of non-adherence to standard asthma preventer treatment (inhaled steroids) on response to biologic treatment (mepolizumab) in people with severe asthma
This study looks at people with severe asthma treated with a specialised drug called mepolizumab. Researchers want to find out if skipping or missing daily steroid inhalers stops mepolizumab from working properly. By checking health records, the team hopes to learn how best to support patients with their daily treatments.
United Kingdom · England - recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
This study looks at a new medicine called dexpramipexole for severe asthma. It wants to see if the medicine can reduce asthma flare-ups and improve breathing over 52 weeks. Researchers will compare it to a dummy medicine to see if it works and is safe.
Czechia · Spain · Germany